ECSP22054700A - Derivados espiráncos sustituidos de cadena lineal - Google Patents

Derivados espiráncos sustituidos de cadena lineal

Info

Publication number
ECSP22054700A
ECSP22054700A ECSENADI202254700A ECDI202254700A ECSP22054700A EC SP22054700 A ECSP22054700 A EC SP22054700A EC SENADI202254700 A ECSENADI202254700 A EC SENADI202254700A EC DI202254700 A ECDI202254700 A EC DI202254700A EC SP22054700 A ECSP22054700 A EC SP22054700A
Authority
EC
Ecuador
Prior art keywords
spiranch
derivatives
linear chain
chain substituted
protein
Prior art date
Application number
ECSENADI202254700A
Other languages
English (en)
Inventor
Xiangjun Deng
Lichao Fang
Olivier Alexis Georges Querolle
Yanping Xu
Lianzhu Liu
Xuedong Dai
Nicolas Freddy J Darville
Johannes Wilhelmus John F Thuring
Alicia Tee Fuay Ng
Edward Cleator
Qiwu Zhao
Vineet Pande
William Maton
Gregor Thomas Urbanietz
Wei Cai
Ming Li
Kangying Li
Yingtao Liu
Liqiang Fu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP22054700A publication Critical patent/ECSP22054700A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a agentes farmacéuticos útiles para la terapia y/o profilaxis en un mamífero, a una composición farmacéutica que comprende tales compuestos y a su uso como inhibidores de la interacción proteína/proteína de la menina/MLL, útiles para tratar enfermedades tales como el cáncer, que incluye, sin carácter limitante, leucemia, síndrome mielodisplásico (SMD) y neoplasias mieloproliferativas (NMP); y diabetes.
ECSENADI202254700A 2019-12-19 2022-07-12 Derivados espiráncos sustituidos de cadena lineal ECSP22054700A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019126760 2019-12-19
US202062961775P 2020-01-16 2020-01-16
CN2020126595 2020-11-04

Publications (1)

Publication Number Publication Date
ECSP22054700A true ECSP22054700A (es) 2022-11-30

Family

ID=76476870

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202254700A ECSP22054700A (es) 2019-12-19 2022-07-12 Derivados espiráncos sustituidos de cadena lineal

Country Status (21)

Country Link
US (1) US12473295B2 (es)
EP (1) EP4077312A4 (es)
JP (3) JP7554829B2 (es)
KR (1) KR20220118500A (es)
CN (4) CN118255773A (es)
AU (1) AU2020404305A1 (es)
CA (1) CA3161045A1 (es)
CL (3) CL2022001583A1 (es)
CO (1) CO2022009085A2 (es)
CR (1) CR20220346A (es)
DO (1) DOP2022000125A (es)
EC (1) ECSP22054700A (es)
IL (1) IL293965A (es)
JO (1) JOP20220154A1 (es)
MX (1) MX2022007652A (es)
PE (1) PE20230162A1 (es)
PH (1) PH12022551502A1 (es)
TW (2) TWI878414B (es)
UA (1) UA129208C2 (es)
UY (1) UY38988A (es)
WO (1) WO2021121327A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506922A (ja) 2017-01-31 2020-03-05 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物
CN118255773A (zh) 2019-12-19 2024-06-28 詹森药业有限公司 取代的直链螺环衍生物
PE20221582A1 (es) 2019-12-19 2022-10-06 Arvinas Operations Inc Compuestos y metodos para la degradacion dirigida de receptor de androgenos
CA3215379A1 (en) 2021-05-08 2022-11-17 Olivier Alexis Georges Querolle Substituted spiro derivatives
KR20240005747A (ko) * 2021-05-08 2024-01-12 얀센 파마슈티카 엔브이 치환된 스피로 유도체
KR20240006631A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
AU2022271993A1 (en) 2021-05-11 2024-01-04 Janssen Pharmaceutica Nv Combination therapies
JP2024521879A (ja) 2021-06-01 2024-06-04 ヤンセン ファーマシューティカ エヌ．ベー． 置換フェニル－１Ｈ－ピロロ［２，３－ｃ］ピリジン誘導体
BR112023025436A2 (pt) 2021-06-03 2024-02-27 Janssen Pharmaceutica Nv Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
JP2024525145A (ja) * 2021-06-17 2024-07-10 ヤンセン ファーマシューティカ エヌ．ベー． がんなどの疾患の治療のための（ｒ）－ｎ－エチル－５－フルオロ－ｎ－イソプロピル－２－（（５－（２－（６－（（２－メトキシエチル）（メチル）アミノ）－２－メチルヘキサン－３－イル）－２，６－ジアザスピロ［３．４］オクタン－６－イル）－１，２，４－トリアジン－６－イル）オキシ）ベンズアミドベシル酸塩
AU2022399756A1 (en) * 2021-12-03 2024-06-27 Bionova Pharmaceuticals Ltd. Carbonyl substituted diazaspiro compounds and its use
AR130379A1 (es) * 2022-09-02 2024-12-04 Hutchmed Ltd Compuestos de triazina y usos de los mismos
CN120529900A (zh) 2022-11-24 2025-08-22 奥莱松基因组股份有限公司 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合
TW202448429A (zh) 2023-04-17 2024-12-16 比利時商健生藥品公司 組合治療
WO2025082444A2 (en) 2023-10-20 2025-04-24 Janssen Pharmaceutica Nv (r) -n-ethyl-5-fluoro-n-isopropyl-2- ( (5- (2- (6- ( (2-methoxyethyl) (methyl) amino) -2-methylhexan-3-yl) -2, 6-diazaspiro [3.4] octan-6-yl) -1, 2, 4-triazin-6-yl) oxy) benzamide, formulations and dosage regimens thereof, for use in treating cancer
CN120365200B (zh) * 2025-04-18 2025-11-11 北京蓝博特科技有限公司 一种(s)-2-(3,5-二甲基苯基)吡咯烷盐酸盐的制备方法

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2791732B2 (ja) * 1992-04-02 1998-08-27 小野薬品工業株式会社 ３′−アミノ−２′−ヒドロキシアセトフェノンの製造方法
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
PL372145A1 (en) 2002-02-19 2005-07-11 Cv Therapeutics, Inc. Partial and full agonists of a sb 1 /sb adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
ES2282731T3 (es) 2002-12-23 2007-10-16 Janssen Pharmaceutica N.V. Derivados de 1-piperidin-4-il-4-azetidin-3-il-piperazina sustituida y su uso como antagonistas de neuroquininas.
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
US20080102068A1 (en) 2005-01-19 2008-05-01 Coleman Paul J Mitotic Kinesin Inhibitors
GB0713602D0 (en) 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
JP5343975B2 (ja) 2008-10-06 2013-11-13 日本電気株式会社 無線通信装置、無線通信システム、無線通信装置の制御方法、及びプログラム
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
JP2011026305A (ja) 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
BR112012003870B1 (pt) 2009-08-20 2018-11-21 Bayer Intellectual Property Gmbh derivados de sulfeto substituídos com 3-triazolilfenila, seu uso, seu processo de preparação e seus intermediários, composições agroquímicas, seu processo de preparação, e processo para combate de parasitas animais
US8993552B2 (en) 2009-09-04 2015-03-31 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
TW201204732A (en) 2010-07-09 2012-02-01 Leo Pharma As Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
WO2012082436A2 (en) 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
GB201021623D0 (en) 2010-12-21 2011-02-02 Isis Innovation Detection of acute myeloid leukaemia
CN103781780B (zh) 2011-07-28 2015-11-25 赛尔佐姆有限公司 作为jak抑制剂的杂环基嘧啶类似物
WO2013018404A1 (ja) 2011-08-01 2013-02-07 オリンパスメディカルシステムズ株式会社 挿入部形状表示装置
AU2011376717A1 (en) 2011-09-14 2014-03-20 Proximagen Limited New enzyme inhibitor compounds
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
CN103664991B (zh) 2012-09-19 2016-12-28 中国科学院福建物质结构研究所 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
EP2920171B1 (en) 2012-11-16 2018-08-29 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
PL2935222T3 (pl) 2012-12-21 2019-02-28 Epizyme Inc Inhibitory PRMT5 i ich zastosowania
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2014164543A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
RU2019131017A (ru) 2013-10-21 2019-11-25 Мерк Патент Гмбх Соединения гетероарила в качестве ингибиторов btk и их применение
WO2015171738A2 (en) 2014-05-06 2015-11-12 The Procter & Gamble Company Fragrance compositions
WO2015191701A1 (en) 2014-06-10 2015-12-17 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
EP3160477A4 (en) 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CN105330698B (zh) * 2014-07-04 2019-05-28 齐鲁制药有限公司 螺环芳基磷氧化物和硫化物
PL3165530T3 (pl) 2014-07-04 2019-07-31 Qilu Pharmaceutical Co., Ltd Spirocykliczny arylowy tlenek fosforu (V) i arylowy siarczek fosforu (V)
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
US20170275302A1 (en) * 2014-10-14 2017-09-28 Alexander Pasternak Inhibitors of the renal outer medullary potassium channel
WO2016081732A1 (en) 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
GEP20197050B (en) 2014-12-18 2019-12-10 Pharmaceutical Company Limited Takeda Solid state forms of fused heteroaromatic pyrrolidinones
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CU20170105A7 (es) 2015-02-24 2017-10-05 Pfizer Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
KR20180103053A (ko) 2015-12-22 2018-09-18 비타이 파마슈티컬즈, 인코포레이티드 메닌-mll 상호작용의 억제제
EP4643952A3 (en) 2016-01-26 2026-01-14 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1
KR102419524B1 (ko) 2016-03-16 2022-07-08 쿠라 온콜로지, 인크. 메닌-mll의 가교된 이환식 억제제 및 사용 방법
BR112018068703B1 (pt) 2016-03-16 2024-02-06 Kura Oncology, Inc. Inibidores substituídos de menin-mll e métodos de uso
WO2017192543A1 (en) 2016-05-02 2017-11-09 Regents Of The University Of Michigan Piperidines as menin inhibitors
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
CA3024180A1 (en) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
CN109689815B (zh) 2016-09-06 2022-06-14 三键有限公司 热固化型导电性胶粘剂
WO2018050686A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
BR112019004691A2 (pt) 2016-09-14 2019-06-25 Janssen Pharmaceutica Nv inibidores bicíclicos em espiro da interação menina-mll
ES2966316T3 (es) 2016-09-14 2024-04-19 Janssen Pharmaceutica Nv Inhibidores bicíclicos fusionados de interacción de MENIN-MLL
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CN118359610A (zh) 2016-09-16 2024-07-19 生命医药有限责任公司 Menin-mll相互作用的抑制剂
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
KR102513564B1 (ko) 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 아제판 억제제
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
MX2019015177A (es) 2017-06-16 2020-02-07 Beta Pharma Inc Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas.
IL271946B (en) 2017-07-09 2022-09-01 Biosight Ltd Combination cancer therapy
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
GB201720077D0 (en) 2017-12-01 2018-01-17 Univ Oxford Innovation Ltd Leukaemic stem cell
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
WO2019120209A1 (en) 2017-12-20 2019-06-27 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-mll interaction
EA202190623A1 (ru) 2018-08-27 2021-05-21 Сумитомо Дайниппон Фарма Ко., Лтд. Оптически активное азабициклическое производное
CN113164443A (zh) 2018-09-26 2021-07-23 库拉肿瘤学公司 用多发性内分泌抑癌蛋白抑制剂治疗血液系统恶性肿瘤
CA3122371A1 (en) 2018-12-07 2020-06-11 University Of Maryland, Baltimore Non-atp/catalytic site p38 mitogen activated protein kinase inhibitors
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
CA3141404A1 (en) 2019-06-14 2020-12-17 Disarm Therapeutics, Inc. Inhibitors of sarm1
KR102924600B1 (ko) 2019-12-18 2026-02-09 솔루스첨단소재 주식회사 유기 화합물 및 이를 이용한 유기 전계 발광 소자
CN118255773A (zh) 2019-12-19 2024-06-28 詹森药业有限公司 取代的直链螺环衍生物
CN111297863B (zh) 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
EP4132932A4 (en) 2020-04-07 2024-04-17 Syndax Pharmaceuticals, Inc. COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF
WO2022114164A1 (ja) 2020-11-30 2022-06-02 アステラス製薬株式会社 ヘテロアリールカルボキシアミド化合物
CA3215379A1 (en) 2021-05-08 2022-11-17 Olivier Alexis Georges Querolle Substituted spiro derivatives
KR20240005747A (ko) 2021-05-08 2024-01-12 얀센 파마슈티카 엔브이 치환된 스피로 유도체
AU2022271993A1 (en) 2021-05-11 2024-01-04 Janssen Pharmaceutica Nv Combination therapies
KR20240006631A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
AU2022271791A1 (en) 2021-05-12 2024-01-04 Board Of Regents, The University Of Texas System Combinations for treatment of cancer
JP2024521879A (ja) 2021-06-01 2024-06-04 ヤンセン ファーマシューティカ エヌ．ベー． 置換フェニル－１Ｈ－ピロロ［２，３－ｃ］ピリジン誘導体
BR112023025436A2 (pt) 2021-06-03 2024-02-27 Janssen Pharmaceutica Nv Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
JP2024525145A (ja) 2021-06-17 2024-07-10 ヤンセン ファーマシューティカ エヌ．ベー． がんなどの疾患の治療のための（ｒ）－ｎ－エチル－５－フルオロ－ｎ－イソプロピル－２－（（５－（２－（６－（（２－メトキシエチル）（メチル）アミノ）－２－メチルヘキサン－３－イル）－２，６－ジアザスピロ［３．４］オクタン－６－イル）－１，２，４－トリアジン－６－イル）オキシ）ベンズアミドベシル酸塩
AU2022399756A1 (en) * 2021-12-03 2024-06-27 Bionova Pharmaceuticals Ltd. Carbonyl substituted diazaspiro compounds and its use
KR20240121720A (ko) 2021-12-15 2024-08-09 다나-파버 캔서 인스티튜트 인크. 메닌-mll 후성유전학적 복합체 파괴에 의한 위장관 기질 종양(gist)의 치료 표적화
US20250152591A1 (en) * 2022-02-04 2025-05-15 Kura Oncology, Inc. Treatment of hematological malignancies with menin inhibitors and p-glycoprotein inhibitors
AU2023269033A1 (en) 2022-05-09 2024-11-21 Syndax Pharmaceuticals, Inc. Menin-mll inhibitors for the treatment of cancer
WO2024114666A1 (en) 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor
WO2024114662A1 (en) 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Cyclobutyl substituted bicyclic compounds
JP2025541695A (ja) 2022-11-30 2025-12-23 ヤンセン ファーマシューティカ エヌ．ベー． 置換１－フェニル－３，４－ジヒドロピリド［３，４－ｄ］ピリミジン－２－オン誘導体
EP4626426A1 (en) 2022-11-30 2025-10-08 JANSSEN Pharmaceutica NV Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
TW202448429A (zh) 2023-04-17 2024-12-16 比利時商健生藥品公司 組合治療

Also Published As

Publication number Publication date
EP4077312A4 (en) 2024-01-17
CL2023001530A1 (es) 2023-11-03
JOP20220154A1 (ar) 2023-01-30
JP7554829B2 (ja) 2024-09-20
PE20230162A1 (es) 2023-02-01
CL2023001531A1 (es) 2023-11-03
CN114867721A (zh) 2022-08-05
JP2026035699A (ja) 2026-03-04
CN118255774A (zh) 2024-06-28
TW202138367A (zh) 2021-10-16
JP2023506530A (ja) 2023-02-16
TWI878414B (zh) 2025-04-01
DOP2022000125A (es) 2022-08-31
CR20220346A (es) 2022-10-26
CL2022001583A1 (es) 2023-02-03
JP2024138279A (ja) 2024-10-08
US20230142285A1 (en) 2023-05-11
UY38988A (es) 2021-06-30
WO2021121327A1 (en) 2021-06-24
UA129208C2 (uk) 2025-02-05
AU2020404305A1 (en) 2022-08-04
KR20220118500A (ko) 2022-08-25
CO2022009085A2 (es) 2022-07-08
TW202525813A (zh) 2025-07-01
JP7781961B2 (ja) 2025-12-08
EP4077312A1 (en) 2022-10-26
PH12022551502A1 (en) 2023-04-24
US12473295B2 (en) 2025-11-18
IL293965A (en) 2022-08-01
CN118255773A (zh) 2024-06-28
CN118344372A (zh) 2024-07-16
MX2022007652A (es) 2022-09-23
CA3161045A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
ECSP22054700A (es) Derivados espiráncos sustituidos de cadena lineal
UY39795A (es) DERIVADOS DE FENIL-1H-PIRROLO[2,3-c]PIRIDINA SUSTITUIDOS
MX2019002959A (es) Inhibidores biciclicos condensados de la interaccion de menina-mll.
MX2019002962A (es) Inhibidores espirobiciclicos de la interaccion de menina-mll.
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2007002166A1 (es) Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
UY35293A (es) Isotiazoles sustituidos con amino
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
HN2003000162A (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
MX2023013174A (es) Derivados espiro sustituidos.
MX2023013176A (es) Derivados espiro sustituidos.
BR112016002311A2 (pt) combinações de inibidor de cinase de pim
CO2023018577A2 (es) Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2-metoxietil)(metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cáncer
MX391405B (es) Inhibidores de azepano de la interacción menina-mll.
BR112023025436A2 (pt) Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
CL2011000647A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de enlace de la proteina smac al iap; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades proliferativas. (divisional de la solicitud 2234-2007).
CL2011000646A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores del enlace de la proteina smac al iap; composicion farmaceutica que los comprende; util en el tratamiento de enfermedades proliferativas. (divisional solicitud 2234-2007).
AR049380A1 (es) Mezclas fungicidas conteniendo derivados de triazolopirimidinas